Chronic hepatitis C: DAA cure and the AU Section 100 prescribing pathway

Chronic hepatitis C (CHC) — detectable HCV RNA for more than six months — was, until 2016, a condition for which treatment was difficult, poorly tolerated, and inconsistently effective. The introduction of direct-acting antiviral (DAA) medications transformed this landscape: HCV is now curable in over 95% of patients with pangenotypic oral regimens of 8–12 weeks, available through Australia’s PBS Section 100 community prescribing pathway since March 2016.

Australia has approximately 100,000 people living with chronic HCV, with prevalence falling rapidly as DAA access continues. Over 90% of new infections occur through injecting drug use. The birth cohort of 1955–1975 carries disproportionate burden from pre-screening-era blood products and procedures. Aboriginal and Torres Strait Islander peoples experience two to three times the general population prevalence. Prisoners carry approximately 30% prevalence.

The GP role in hepatitis C encompasses case finding in at-risk groups, confirming the diagnosis with HCV RNA PCR, staging liver disease with fibrosis assessment, checking drug interactions, and — after ASHM accreditation — prescribing curative DAA therapy directly in general practice without specialist referral for uncomplicated patients. The ASHM hepatitis C resources and GESA consensus statement are the primary Australian references.

A. Core clinical — the AU general practice framework

Who to test

Anti-HCV antibody testing is indicated for:

• People who have ever injected drugs, even once — the dominant transmission route in Australia (>85% of new infections).
• Birth cohort 1955–1975 — pre-1990 transfusion recipients, surgical procedures without modern infection control.
• Aboriginal and Torres Strait Islander peoples — screen at health assessments (item 715).
• Prisoners and former prisoners — approximately 30% prevalence; screen on health assessments.
• Men who have sex with men (MSM), particularly those with HIV or engaged in chemsex — sexually transmitted HCV clusters in this population.
• Refugees and migrants from Egypt (genotype 4), Pakistan, Mongolia, Eastern Europe, and Southeast Asia — variable prevalence up to 10%.
• Recipients of tattoos or piercings in non-sterile settings — particularly outside Australia.
• Occupational needlestick exposures — ~1.8% transmission rate per exposure.

Testing pathway:

1. Anti-HCV antibody — positive indicates past or present infection. A positive result requires confirmation.
2. HCV RNA PCR (qualitative or quantitative) — if anti-HCV positive: detectable RNA = active infection; undetectable RNA = cleared infection (spontaneously or post-treatment).
3. HCV genotype — historically critical; most current regimens are pangenotypic, but genotype is still useful in some clinical scenarios.

Diagnosis and fibrosis assessment

Once chronic infection is confirmed:

• Baseline bloods — LFTs (ALT, AST, bilirubin, albumin, GGT), FBE (thrombocytopaenia — marker of cirrhosis), INR, creatinine/eGFR.
• Co-infection screening — HIV (4th-generation antigen/antibody), HBV (HBsAg, anti-HBc, anti-HBs), HAV antibody (for vaccination planning).
• Fibrosis assessment — staging liver disease determines urgency and some regimen choices:
  • FIB-4 score = (age × AST) / (platelets × √ALT); low (below 1.30) rules out advanced fibrosis in most; high (above 3.25) raises cirrhosis concern.
  • APRI = (AST/ULN × 100) / platelets — similar utility.
  • FibroScan (transient elastography) — preferred where available; point-of-care, non-invasive, quantitative liver stiffness in kPa. Available at many GP practices and hepatology units.
  • Liver biopsy — rarely required in the DAA era.
• HCC surveillance baseline — liver ultrasound + AFP at baseline for patients with cirrhosis (F4).
• Pregnancy test in women of reproductive age — ribavirin (used in some decompensated cirrhosis regimens) is teratogenic; standard DAA regimens are Category B/C and generally deferred in pregnancy.
• Drug interaction check — mandatory before prescribing (see Section B).

Treatment regimens — the DAA era

First-line pangenotypic options (PBS Section 100 Authority Required Streamlined):

1. Glecaprevir/pibrentasvir (Maviret) 8 weeks:

• Treatment-naive patients with no cirrhosis or compensated cirrhosis (F0–F3).
• 12 weeks for compensated cirrhosis (F4) or treatment-experienced patients.
• Contraindicated in decompensated cirrhosis (Child-Pugh B/C) — contains a protease inhibitor.

2. Sofosbuvir/velpatasvir (Epclusa) 12 weeks:

• All genotypes; all fibrosis stages including decompensated cirrhosis.
• Decompensated cirrhosis: sofosbuvir/velpatasvir plus ribavirin for 12 weeks, or sofosbuvir/velpatasvir alone for 24 weeks — specialist input required.
• Fewer problematic drug interactions than glecaprevir/pibrentasvir for some patient profiles.

3. Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) 12 weeks:

• Rescue regimen for prior DAA failure — PBS Section 100 Authority Required (Telephone).
• Specialist initiation typically required.

Cure definition: Sustained virological response at 12 weeks post-treatment (SVR12) — undetectable HCV RNA 12 weeks after completing therapy = virological cure. SVR12 rates exceed 95% with current first-line regimens across all genotypes.

B. Evidence appraisal — DAA efficacy, GP prescribing, and treatment-as-prevention

Glecaprevir/pibrentasvir (Maviret)

Phase 3 ENDURANCE and EXPEDITION trials demonstrated SVR12 rates of 97–99% across genotypes 1–6 in non-cirrhotic treatment-naive patients on the 8-week regimen. The 8-week duration reduces treatment burden and cost compared with 12-week alternatives. The SURVEYOR and EXPEDITION-4 trials established safety and efficacy in renal impairment — this is the preferred regimen when eGFR below 30, as glecaprevir/pibrentasvir undergoes primarily biliary/faecal elimination.

Sofosbuvir/velpatasvir (Epclusa) — ASTRAL trials

The ASTRAL-1 trial (Feld et al., NEJM 2015) enrolled 740 patients with genotypes 1, 2, 4, 5, or 6: SVR12 of 99% with sofosbuvir/velpatasvir versus 76% with placebo. ASTRAL-2 and ASTRAL-3 confirmed efficacy in genotypes 2 and 3. The ASTRAL-4 trial established sofosbuvir/velpatasvir plus ribavirin in decompensated cirrhosis (SVR12 ~83%). The pangenotypic coverage and inclusion of decompensated cirrhosis make Epclusa the broadest-coverage first-line option.

GP-led Section 100 prescribing

Australian evidence consistently demonstrates equivalent SVR12 rates when DAA therapy is prescribed and managed by accredited GP prescribers compared with hepatology specialists. The Section 100 community prescriber programme, led by ASHM, has dramatically expanded HCV treatment access — particularly for people who inject drugs, who are less likely to attend specialist hepatology services but regularly see their GP or attend community health centres. GPs prescribe the majority of DAA courses in Australia.

Treatment in active drug use — “treatment as prevention”

Multiple cohort studies in Australia and internationally have confirmed that people who actively inject drugs achieve equivalent SVR12 rates (>90%) with appropriate adherence support. Australian modelling supports HCV treatment as a transmission-reduction strategy — each person cured removes a potential infector from the transmission network. ASHM and GESA both endorse treating active drug users without requiring abstinence as a precondition.

C. Drug interactions and pre-treatment essentials

Drug interactions with DAA regimens are clinically significant and must be systematically checked using the Liverpool HEP Drug Interactions checker (hep-druginteractions.org) for every patient before prescribing.

Key interactions:

• Statins — glecaprevir/pibrentasvir substantially increases rosuvastatin AUC by ~2-fold and atorvastatin AUC by ~10-fold; dose reduction or temporary statin cessation is required. Sofosbuvir/velpatasvir has lesser statin interaction.
• Anticonvulsants (carbamazepine, phenytoin, phenobarbitone, rifampicin) — potent CYP inducers that reduce DAA plasma levels to sub-therapeutic concentrations; change the anticonvulsant or select an alternative DAA regimen with specialist input.
• Oral contraceptive pills — may have reduced efficacy with some DAA regimens; recommend barrier contraception during treatment.
• Amiodarone — combined with sofosbuvir-containing regimens, can cause severe symptomatic bradycardia (including cardiac arrest); avoid combination or monitor closely in hospital.
• Warfarin — some DAA regimens affect INR; more frequent INR monitoring required.
• Antiretrovirals — in HIV co-infection, individual antiretroviral combinations have specific interactions; check individually.

HBV reactivation screening — mandatory before starting DAA therapy:

• Screen HBsAg and anti-HBc for all patients.
• If HBsAg positive: concurrent HBV antiviral therapy (entecavir or tenofovir) is required — DAA treatment can cause HBV reactivation with severe hepatitis.
• If anti-HBc positive and HBsAg negative: monitor LFTs during DAA therapy; antiviral prophylaxis in immunosuppressed patients.

Adherence support — particularly important for patients with active substance use; peer worker involvement, integration with opioid agonist therapy (OAT) services, and flexible appointment models improve completion rates.

D. Australian operations

Section 100 PBS prescribing — GP pathway

The PBS Section 100 Highly Specialised Drugs Programme funds:

• Glecaprevir/pibrentasvir (Maviret) — Authority Required Streamlined; GP/NP after ASHM accreditation.
• Sofosbuvir/velpatasvir (Epclusa) — Authority Required Streamlined; GP/NP after ASHM accreditation.
• Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) — Authority Required Telephone; typically specialist.
• Ribavirin — Section 100 for specific decompensated cirrhosis regimens; specialist involvement.

GP accreditation pathway: Complete the ASHM hepatitis C s100 prescriber programme — available online at hepatitisc.ashm.org.au. The course covers diagnosis, fibrosis staging, regimen selection, drug interactions, HBV reactivation, and SVR monitoring. Takes approximately 2–4 hours. Strongly recommended for any GP who has HCV patients in their practice.

Referral triggers for specialist involvement:

• Decompensated cirrhosis (Child-Pugh B/C — jaundice, ascites, encephalopathy, coagulopathy).
• Prior DAA treatment failure.
• HIV co-infection requiring complex antiretroviral interaction management.
• Complex or unclear drug interactions.

MBS items

MBS Online: items 23, 36, 44 (standard consultations); GPCCMP (items 965/967) for complex chronic hepatitis C management; item 715 (ATSI Health Assessment including HCV screening); items 701/703/705 (refugee health assessments including HCV serology); item 73881 (HCV RNA quantitative PCR); items 55028/55036 (liver/abdominal ultrasound for HCC surveillance); items 132/133 (specialist physician consultations for complex cases).

Australian resources

• ASHM — clinical tools, prescriber accreditation, decision-making algorithms.
• Hepatitis Australia — patient helpline 1800 437 222; state hepatitis organisations (Hepatitis NSW, Hepatitis Victoria, etc.).
• GESA — gastroenterology/hepatology clinical guidance.
• Liverpool HEP Drug Interactions checker — drug interaction tool (hep-druginteractions.org); use for every patient before prescribing.

Harm reduction services

• Needle and Syringe Programmes (NSP) — state-funded; widely available in urban and regional areas; free access.
• Opioid Agonist Therapy (OAT) — methadone and buprenorphine; reduces HCV transmission and supports treatment adherence; PBS-funded.
• Peer-led services — Australian Injecting and Illicit Drug Users League (AIVL); state drug user organisations.

Notifiable disease

HCV is notifiable in all Australian jurisdictions. Laboratory tests typically trigger automatic notification; confirm local jurisdiction requirements for clinical notification.

Hepatitis A and B vaccination

All patients with chronic hepatitis C who are not immune should be vaccinated against hepatitis A and B — superinfection with either can accelerate liver disease progression. HAV and HBV vaccines are PBS-funded for eligible patients with chronic liver disease.

E. Special populations

People who inject drugs. As noted above, active drug use is not a contraindication. Integrating HCV treatment into opioid agonist therapy clinics, community health centres, and needle and syringe programmes maximises access. Peer worker involvement and flexible appointments improve adherence. SVR12 rates are equivalent to non-injecting populations with appropriate support.

Cirrhosis and advanced liver disease. Compensated cirrhosis (Child-Pugh A, F4 on FibroScan) can be treated by accredited GPs with 12-week glecaprevir/pibrentasvir or 12-week sofosbuvir/velpatasvir. Decompensated cirrhosis (ascites, encephalopathy, coagulopathy) — refer to hepatology; sofosbuvir/velpatasvir plus ribavirin, avoiding protease inhibitors. Post-cure HCC surveillance continues for all cirrhotic patients regardless of SVR.

HIV co-infection. SVR12 rates are equivalent to HCV monoinfection with appropriate antiretroviral interaction checking. Many antiretroviral regimens are compatible with DAA therapy; some require regimen adjustment. Infectious diseases or hepatology co-management is recommended.

Renal impairment (eGFR below 30 or dialysis). Glecaprevir/pibrentasvir is the preferred regimen — no dose adjustment required and no significant renal pharmacokinetic changes. Sofosbuvir-containing regimens accumulate renally and require specialist guidance below eGFR 30.

Pregnancy. Standard DAA regimens are generally deferred until after delivery — safety data in pregnancy are limited, and ribavirin is absolutely contraindicated (teratogenic). In women planning pregnancy, completing HCV treatment before conception is ideal. Post-partum treatment is the standard approach. Breastfeeding — limited data; generally deferred pending further studies unless treatment is clinically urgent.

Refugees and migrants from endemic regions. Screen at refugee health assessments (items 701/703/705). Language and cultural barriers are significant; interpreter services and culturally appropriate community organisations improve uptake. Hepatitis C is highly stigmatised in many cultures — careful, destigmatising communication is essential.

When to escalate

• Decompensated cirrhosis (ascites, encephalopathy, coagulopathy) — refer to hepatology before initiating treatment.
• Prior DAA failure — specialist consultation; Vosevi regimen requires telephone Authority and specialist oversight.
• HIV co-infection — infectious diseases or hepatology co-management for antiretroviral interaction planning.
• HBsAg positive — concurrent HBV antiviral therapy required; gastroenterology or hepatology input.
• Complex drug interactions that cannot be resolved by drug switching — specialist consultation.
• Suspected hepatocellular carcinoma (rising AFP, suspicious liver lesion on ultrasound) — urgent hepatology/oncology referral; HCC is contraindication to DAA until HCC is treated or excluded.
• Unexplained cytopaenia or coagulopathy — haematology/hepatology workup for portal hypertension or alternative cause.

What this article is and is not

This is general health information drawn from current Australian guidelines — ASHM hepatitis C resources, GESA consensus statement, Therapeutic Guidelines, Australian Medicines Handbook — and international guidance including AASLD-IDSA, EASL 2020, and the ASTRAL trial data. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about treatment regimen selection, drug interaction management, need for specialist referral, and post-treatment surveillance are made by your own GP or treating specialist based on your complete clinical picture.

For Australian patient support: Hepatitis Australia helpline 1800 437 222; state hepatitis organisations (Hepatitis NSW, Hepatitis Victoria, etc.); HealthDirect — Hepatitis C; Better Health Channel — Hepatitis C.

---

Sources cited

1. ASHM — Hepatitis C prescriber resources and Section 100 accreditation
2. GESA — Australian and New Zealand Hepatitis C Consensus Statement
3. Therapeutic Guidelines (eTG) — Chronic hepatitis C
4. RACGP
5. Australian Medicines Handbook (AMH)
6. Hepatitis Australia
7. PBS — Section 100 DAA prescribing
8. MBS Online
9. AASLD-IDSA — HCV Guidance
10. EASL 2020 — Recommendations on Treatment of Hepatitis C
11. Feld JJ et al. — ASTRAL-1 trial (sofosbuvir/velpatasvir, NEJM 2015)
12. Burnet Institute — National Hepatitis C Strategy
13. HealthDirect — Hepatitis C
14. Better Health Channel — Hepatitis C